Skyline Embassy Kuala Lumpur (2025)

Get link
Facebook
X
Pinterest
Email
Other Apps

By Editorial Team - March 08, 2025

Skyline Embassy Kuala Lumpur

Discover elevated living at Skyline Embassy, the epitome of luxury in Kuala Lumpur. Situated amidst the prestigious row of embassies, Skyline Embassy sets the Gold Standard for truly bespoke living.

Immerse yourself in opulence with meticulously crafted interiors, breathtaking skyline views, and unrivaled amenities. Experience a lifestyle tailored for you, where every detail reflects the pinnacle of sophistication.

Elevate your status and embrace the epitome of refined living at Skyline Embassy – where exclusivity meets elegance.

TSLAW Land, a prestigious Malaysian developer in Kuala Lumpur, brings decades of expertise in property development, supported by its parent company, TSLAW Group, boasting a portfolio of prime land assets.

Property Details

Service Residence for sale
Embassy district - surrounded by over 50 embassies
The Linc KL (grocery & F&B) is just downstairs
300m walking distance (5 minutes to Ampang Park MRT & LRT stations)
Rooftop pool on the 65th floor (KL view) and a ballroom in the sky
950m to KLCC
1.5km to TRX & Pavilion KL
50% completed, no need to wait for 3 years, savings on construction interest

Available Unit Types

Type A:

1+1 Bedroom and 1 Bathroom

551 sq.ft.

Type B:

2 Bedrooms and 1 Bathroom

710 sq.ft.

Type C:

2 Bedrooms and 2 Bathrooms

841 sq.ft.

Type D:

2 Bedrooms and 2 Bathrooms

853 sq.ft.

Type E:

2+1 Bedrooms and 2 Bathrooms

853 sq.ft.

Type F:

3 Bedrooms and 2 Bathrooms

1,005 sq.ft.

Location Map

Schedule for Viewing

Enquire Now: Please feel free to contact us for a Free Viewing—we’re here to help!

Related: Pavilion Square Kuala Lumpur

malaysia property

Get link
Facebook
X
Pinterest
Email
Other Apps

Comments

Top 10 ETF Picks for August 2025: Best Funds to Buy Now for Growth, Safety, and Diversification

By Editorial Team - August 04, 2025

Here are the top 10 ETF picks for August 2025, along with insights on whether they are worth considering for investment right now. This list blends global equity leaders, sector specialists in defense and metals, and broad market trackers—balancing momentum with diversification and risk management. Current market conditions and upcoming events like the U.S. Federal Reserve’s September meeting make August a timely opportunity to reallocate or accumulate: 1. SPDR S&P 500 ETF Trust (SPY) or Vanguard S&P 500 ETF (VOO) Broad U.S. equity exposure; strong performers with SPY up 8.9% YTD and focused on the AI rally and potential post-rate-cut growth ( 1 , 2 ). Would buy: Yes, for long-term core holding and growth. 2. iShares Core S&P 500 ETF (IVV) Similar to SPY/VOO, highly liquid, low expense ratio. Would buy: Yes, for passive U.S. equity exposure ( 2 ). 3. Mirae Asset Defence Tech ETF or MarketVector Global Defense Industry ETF Defense sector ETFs are up 45%...

Best Gold and Silver ETFs of 2025: Should You Buy Today?

By Editorial Team - July 31, 2025

Gold and silver ETFs are outperforming the S&P 500 index. But do these precious metals deserve a place in your investment portfolio? We provide a list of the best precious metals ETFs by 2025 performance, as well as the benefits and risks that investors need to know before buying these funds. The best gold and silver ETFs of 2025 stand out due to exceptional performance, low expense ratios, and reliable tracking of precious metals’ prices. Here are the top options across global and key regional markets as of July 2025: Best Gold ETFs of 2025 SPDR Gold MiniShares Trust (GLDM) 1-Year Return: 43.90% Expense Ratio: 0.10% Notes: Best performing gold ETF, tracks physical gold, high liquidity, and cost-effective for retail investors ( 1 , 2 ). iShares Gold Trust Micro (IAUM) 1-Year Return: 43.86% Expense Ratio: 0.09% Notes: Nearly matches GLDM in returns, with the lowest expense ratio among major gold ETFs ( 1 ). abrdn Physical Gold Shares ETF (S...

Top Gold ETFs to Watch in 2025: Best Picks for Strong Returns and Low Costs

By Editorial Team - August 01, 2025

Top gold ETFs to watch in 2025 span U.S., Indian, Europe and Chinese markets, offering both physical gold exposure and mining stock leverage. Based on the latest performance, expense ratios, and trends, key ETFs include: SPDR Gold MiniShares Trust (GLDM) : The best-performing gold ETF by one-year return in 2025, up around 44%, with a very low expense ratio (0.10%). It tracks physical gold closely and is highly liquid, making it a top choice for cost-conscious investors seeking strong recent gains ( 2 , 1 ). iShares Gold Trust Micro (IAUM) : Nearly matching GLDM’s performance with a 43.86% one-year gain and an even lower expense ratio (0.09%), this is an excellent low-cost option for gold exposure ( 2 ). abrdn Physical Gold Shares ETF (SGOL) : With about a 43.8% one-year return and expense ratio around 0.17%, this fund holds physical gold bullion and appeals to investors seeking stable, direct gold exposure ( 2 , 1 ). GraniteShares Gold Trust (BAR) : Tracks physica...

Top XRP ETFs to Watch in 2025: Dominating Holdings, Low Fees, and Performance Insights

By Editorial Team - July 26, 2025

As the cryptocurrency market matures in 2025, XRP ETFs have emerged as essential instruments for investors seeking regulated and accessible exposure to this dynamic digital asset. With a growing variety of futures-based and physically backed spot ETFs now available across major markets like the U.S., Canada, and Europe, understanding the nuances of these products—including their fee structures, holdings, and performance—is crucial for making informed investment decisions. This article highlights the top XRP ETFs to watch in 2025, providing deep insights into their dominating holdings, low fees, and recent market impact, all organized in a clear list format for easy navigation. Whether you are a long-term investor or an active trader, this guide will help you identify opportunities and risks in the evolving XRP ETF landscape. 1. Leading XRP ETFs in 2025 ProShares Ultra XRP ETF (UXRP) Type: 2x leveraged futures-based ETF listed in the U.S. Launched: July 18, 2025 Key Features...

Top 10 Pharma Companies by Market Cap in 2025

By Editorial Team - August 02, 2025

Here are the top 10 pharmaceutical companies by market cap as of July 2025. The pharmaceutical industry remains robust amid evolving market dynamics, driven by innovation, strategic expansions, and shifting healthcare policies. This mid-2025 update integrates the first half's (H1) financial results to provide readers with a clear snapshot of leading companies’ performance and trajectory. Aug 1, 2025 Update: @POTUS sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. ( source ) In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). Credit: CompaniesMarketCap.com ...

Top 10 Pharmaceutical Companies by Revenue in 2025 (July Edition)

By Editorial Team - July 29, 2025

Here are the top 10 pharmaceutical companies by revenue as of 2025, primarily based on first quarter 2025 revenue data. Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 , 2 , 3 ). Aug 1, 2025 Update: @POTUS sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. ( source ) In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). While earnings and revenue reports are considered lagging indicator...

Top 10 Cancer Drug Companies of 2025

By Editorial Team - August 03, 2025

Merck, Roche and Celgene (now part of Bristol-Myers Squibb) have remained prominent players, but the market dynamics have shifted significantly in recent years. Aug 1, 2025 Update: @POTUS sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. ( source ) This increased competition is fueled by the success of blockbuster drugs like Keytruda (Merck), Tagrisso (AstraZeneca), and Ibrance (Pfizer), as well as the rapid adoption of immunotherapies and targeted treatments ( Verified Market Reports ). Look at 2017. The trio of drugmakers together held a 45.8% share of the market, with longtime cancer leader Roche controlling 26.4% all on its own. In 2024, though, market intelligence firm EvaluatePharma expects to see much more parity. The top three’s share will shrink to 26.2%, with Roche’s dropping all the way down to 11.9%. And the No. 2 through No. 5 companies—BMS, Johnson & Johnson, Pfizer, AstraZeneca and Merck—will boas...

Top 10 Credit Cards for Hospital Bills in Singapore 2025

By Editorial Team - July 11, 2025

If you are looking for the best credit cards for hospital bills in Singapore , you've come to the right place. Whether you're dealing with big doctors' bills right now or regularly spend on your health, you may be interested in a credit card that offers rewards for medical spend. Most credit cards actively exclude hospital spend from earning rewards. So, to make things easier, the experts from Value Champion have scoured the terms & conditions of 100+ cards in Singapore to find which actually do provide cash rebates or miles. Earning Rewards on Hospital Bills & Why We Selected these Cards Medical bills, whether for a doctor or a hospital visit, can be quite expensive and are sometimes difficult to pay off all at once. Facing such a large bill can certainly be daunting, but doing so also presents the opportunity to earn significant cashback or miles (the greater the spend, the greater the return). Additionally, some credit cards offer 0% interest instalment plans wh...

Top 10 Stocks Poised to Outperform in August 2025: AI, Clean Energy, and Tech Leaders to Watch

By Editorial Team - August 02, 2025

As August 2025 unfolds, investors are eagerly seeking opportunities to capitalize on the market’s strongest performers. Driven by rapid advancements in artificial intelligence, the accelerating global energy transition, and robust demand for technology infrastructure, certain companies stand out as frontrunners poised for substantial growth. This article highlights the top 10 stocks expected to outperform in August 2025, providing insights into their recent momentum, sector leadership, and the key trends fueling their rise. Whether you’re looking to boost your portfolio with cutting-edge innovators or aiming for steady gains through resilient industries, these companies represent some of the most compelling investment prospects in the current market landscape. Based on recent trends and analyst forecasts for August 2025, the following companies are expected to outperform: 1. Nvidia (NVDA) NVIDIA (NVDA) is rated a "Strong Buy" by a consensus of analysts, with 44–64 analysts (d...

Did Steve Jobs Refuse Treatment for Pancreatic Cancer?

By Editorial Team - July 09, 2025

It’s been more than 12 years since the passing of Steve Jobs. Legendary Apple Inc., Co-founder Steve Jobs passed away at only 56 years old after battling pancreatic neuroendocrine tumor, a rare form of pancreatic cancer. A growing list of people in the public spotlight have faced pancreatic cancer, including tech innovators, entrepreneurs and influencers. In addition, and connected to Jobs, Jef Raskin, developer of the Macintosh computer, passed away of pancreatic cancer in 2005. And, coincidentally, Dag Kittlaus, creator of Siri, which was acquired by Apple in 2010, was diagnosed with the same exact cancer that took the life of Jobs. Pancreatic neuroendocrine tumors (or PNETs) account for less than 10% of all pancreatic cancer tumors and tend to grow slower than exocrine tumors, the most common type of pancreas tumors. Jobs survived eight years before dying of the disease on Oct. 5, 2011. The five-year survival rate for pancreatic cancer is only 10%. Since PNETs are so uncommon, trea...

Search This Blog

The Consumer Advisor